Dergiler / Journal of the Turkish-German Gynecological Association / 2018 / Cilt: 19 - Sayı: 1

The effect of progesterone use in the first trimester on fetal nuchal translucency

Sayfa
29–33
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Whether the difference in NT was caused by the effect of maternal weight was investigated using the covariance analysis test and maternal weight was not found to be statistically significant in the model (p=0.284).Conclusion: Fetal NT was increased in the progesterone group compared with the untreated group in healthy pregnancies. (J Turk Ger Gynecol Assoc 2018; 19: 29-33)

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To evaluate the possible association between progesterone use in the first trimester of pregnancy and fetal nuchal translucency (NT).Material and Methods: This is an observational case-control study, which was conducted with patients who underwent nuchal scans between March 2015 and February 2016 and consequently delivered live and healthy babies.
📊
Temel Bulgular & Veri:The study group was composed of assisted reproductive technology pregnancies and used intravaginal progesterone 180 mg/day until gestational week 12.
💡
Sonuç & Katkı:Whether the difference in NT was caused by the effect of maternal weight was investigated using the covariance analysis test and maternal weight was not found to be statistically significant in the model (p=0.284).Conclusion: Fetal NT was increased in the progesterone group compared with the untreated group in healthy pregnancies. (J Turk Ger Gynecol Assoc 2018; 19: 29-33)
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: To evaluate the possible association between progesterone use in the first trimester of pregnancy and fetal nuchal translucency (NT).Material and Methods: This is an observational case-control study, which was conducted with patients who underwent nuchal scans between March 2015 and February 2016 and consequently delivered live and healthy babies. The study group was composed of assisted reproductive technology pregnancies and used intravaginal progesterone 180 mg/day until gestational week 12. The control group comprised pregnant women who became pregnant spontaneously without using any progesterone preparation in the first trimester.Results: One hundred sixty-four (57.5%) of 285 patients were in the control group and 121 (42.5%) were in the progesterone group. Age, bodyweight, gravidity, and parity number of previous births and abortus, gestational week, crown-rump lengths, free β-human chorionic gonadotropin, pregnancy-associated plasma protein A, and NT values of the progesterone and control groups were recorded and we investigated whether there was a statistically significant difference between the two groups in terms of these parameters; maternal weight was found to be higher in the progesterone group than in the control group and the difference between the groups was statistically significant (p=0.019 and p=0.025). Whether the difference in NT was caused by the effect of maternal weight was investigated using the covariance analysis test and maternal weight was not found to be statistically significant in the model (p=0.284).Conclusion: Fetal NT was increased in the progesterone group compared with the untreated group in healthy pregnancies. (J Turk Ger Gynecol Assoc 2018; 19: 29-33)

🔖

Bu Makaleye Atıf Yap

ERGÜN, A., GÜRGAN, T., KALEM, M. N., BAKIRARAR, B., KALEM, Z. (2022). The effect of progesterone use in the first trimester on fetal nuchal translucency. Journal of the Turkish-German Gynecological Association, Cilt: 19 - Sayı: 1, 29–33. https://ajindex.com/articles/567512

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Wald NJ, Hackshaw AK. Combining Ultrasound and Biochemistry in First‐Trimester Screening for Down's syndrome. Prenat Diagn 1997; 17: 821-9
  2. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000; 107: 1271-5
  3. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one‐stop clinic: a review of three years’ prospective experience. BJOG 2003; 110: 281-6
  4. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A. Ultrasound Obstet Gynecol 2008; 31: 618-24
  5. Von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, Bahlmann F, Meyberg H, Kossakiewicz A. et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. J Matern-Fetal Neonatal Med 2002; 12: 89-94
  6. Giorlandino C, Cignini P, Padula F, Giannarelli D, d'Emidio L, Aloisi A, et al. Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study. Am J Obstet Gynecol 2015; 212: 335
  7. Wilson RD, Poon LC, Ghidini A. Current controversies in prenatal diagnosis 3: is there still a value in a nuchal translucency screening ultrasound in conjunction with maternal plasma non‐invasive cell‐free DNA testing? Prenatal Diagnosis 2016; 36: 20-4
  8. Baer RJ, Currier RJ, Norton ME, Flessel MC, Goldman S, Towner D, et al. Obstetric, perinatal, and fetal outcomes in pregnancies with false-positive integrated screening results. Obstet Gynecol 2014; 123: 603-9.J Turk Ger Gynecol Assoc 2018; 19: 29-33Namlı Kalem et al.Progesterone and nuchal translucency32 9. Spaggiari E, Czerkiewicz I, Sault C, Dreux S, Galland A, Salomon LJ, et al. Impact of Including or Removing Nuchal Translucency Measurement on the Detection and False-Positive Rates of First-Trimester Down Syndrome Screening. Fetal Diagn Ther 2016; 40: 214-8
  9. Czyzyk A, Podfigurna A, Genazzani AR, Meczekalski B. The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility. Gynecol Endocrinol 2017; 33: 421-4
  10. Costantino M, Guaraldi C, Costantino D. Resolutio